Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
A83-01 (HB3218)
Description:Selective TGF-βRI (ALK5), ALK4 and ALK7 inhibitor. Maintains human hiPSC self renewal, 3D growth matrix component and promotes long-term organoid growth. Aids fibroblast to NSC/cardiomyocyte reprogramming.
Purity:>98%
AY 9944 dihydrochloride (HB3543)
Description:Hedgehog signaling inhibitor. Δ,7-dehydrocholesterol reductase inhibitor.
Purity:>99%
Bisindolylmaleimide IV (HB0137)
Description:Selective, non-competitive PKC / PKA inhibitor
Purity:>98%